Effect of Bioleukin on Blood Cells in Terminal Cancer Patients
Author Information
Author(s): R.T.D. Oliver, D. Crosby, A. Nouril, E. Scott, A. Galazka
Primary Institution: The London Hospital Medical College, London, UK
Hypothesis
Does continuous infusion of recombinant interleukin-2 (bioleukin) affect peripheral blood leucocytes in patients with terminal malignancy?
Conclusion
The study found that bioleukin can safely increase lymphocyte levels in terminal cancer patients without causing lasting side effects.
Supporting Evidence
- Median lymphocyte rebound on day 14 was 3.6 times the pre-treatment level.
- Temporary interruption of treatment led to rapid resolution of side effects.
- Nine of 17 patients required temporary interruption of infusion due to toxicity.
Takeaway
This study tested a medicine called bioleukin on sick patients to see if it could help their blood cells. It worked well and didn't hurt them too much.
Methodology
Seventeen patients with terminal malignancy received two doses of continuous infusion bioleukin, with monitoring of blood cell counts and side effects.
Potential Biases
Potential bias due to the lack of randomization and the small number of patients.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
Patients had terminal testicular, renal, and prostate cancer, and malignant melanoma, with a WHO performance status of 2 or 3.
Want to read the original?
Access the complete publication on the publisher's website